NCT03646188 2026-04-16
Dose Escalation Trial to Evaluate Dose Limiting Toxicity/Maximum Tolerated Dose of Microneedle Arrays Containing Doxorubicin (D-MNA) in Basal Cell Carcinoma (BCC)
SkinJect, Inc.
Phase 1 Terminated
Clinical Trials
4,211 trialsNCT05498220 2026-04-16
Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Terminated
NCT02095184 2026-04-15
GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients
University of Maryland, Baltimore
Phase NA Terminated
NCT03856216 2026-04-15
Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01580618 2026-04-14
Tenecteplase (TNK) for Loculated Pleural Effusions in Patients With Malignancy
Kaiser Permanente
Phase 2/3 Terminated
NCT05189366 2026-04-14
SOPHNEURO
Institut Cancerologie de l'Ouest
Phase NA Terminated
NCT05879185 2026-04-13
A Study of XmAb23104 in People With Sarcoma
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT02819752 2026-04-09
PEACH
Royal Marsden NHS Foundation Trust
Phase 1 Terminated
NCT05567835 2026-04-09
TOGAR
Baylor College of Medicine
Phase 2 Terminated
NCT01366612 2026-04-03
FLUBUTBI
Hackensack Meridian Health
Phase 3 Terminated
NCT02681302 2026-04-03
CPIT001
Hackensack Meridian Health
Phase 1/2 Terminated
NCT04251533 2026-04-03
EPIK-B3
Novartis
Phase 3 Terminated
NCT04438382 2026-04-02
Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis
Eastern Cooperative Oncology Group
Phase 2 Terminated
NCT05076266 2026-04-02
COVID-19 Related Financial Hardship and Distress in Women Who Decline TMIST (EA1151) Participation
Eastern Cooperative Oncology Group
Terminated
NCT05744375 2026-04-02
TRANSCENDER
Spanish Breast Cancer Research Group
Phase 2 Terminated
NCT05765734 2026-04-02
TAS3351
Taiho Oncology, Inc.
Phase 1 Terminated
NCT04221438 2026-04-01
Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement
Eastern Cooperative Oncology Group
Phase 2 Terminated
NCT03150004 2026-03-30
Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
Medical College of Wisconsin
Phase 2 Terminated
NCT03983668 2026-03-30
CMP-001 for Relapsed and Refractory Lymphoma
University of Iowa
Phase 1/2 Terminated
NCT03386357 2026-03-27
Radiotherapy With Pembrolizumab in Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
University of Erlangen-Nürnberg Medical School
Phase 2 Terminated
NCT03960021 2026-03-27
ARFIM
Institut Bergonié
Phase NA Terminated
NCT04234113 2026-03-27
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Sotio Biotech Inc.
Phase 1 Terminated
NCT04762602 2026-03-27
A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations
Hutchmed
Phase 1 Terminated
NCT05036681 2026-03-27
A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01743950 2026-03-25
A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab
University of Wisconsin, Madison
Phase 2 Terminated
NCT01453088 2026-03-24
Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older
Hackensack Meridian Health
Phase 2 Terminated
NCT05059470 2026-03-23
IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATC
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT04877912 2026-03-20
Accurate, Rapid and Inexpensive MRI Protocol for Breast Cancer Screening
University of Chicago
Terminated
NCT04338269 2026-03-19
CONTACT-03
Hoffmann-La Roche
Phase 3 Terminated
NCT03922100 2026-03-18
Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML
Nerviano Medical Sciences
Phase 1/2 Terminated
NCT04789668 2026-03-18
Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT04902040 2026-03-18
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT05275439 2026-03-18
Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML
Shattuck Labs, Inc.
Phase 1 Terminated
NCT03590574 2026-03-16
Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell Lymphoma
Autolus Limited
Phase 1/2 Terminated
NCT05753007 2026-03-16
A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients
Mclean Hospital
Phase 2 Terminated
NCT04676360 2026-03-13
Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma
Massachusetts General Hospital
Phase 2 Terminated
NCT05479123 2026-03-13
Assessing the Impact of Dosage Frequency of Propranolol on Sleep Patterns in Patients With Infantile Hemangiomas
The University of Texas Health Science Center, Houston
Phase 4 Terminated
NCT04796324 2026-03-12
Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.
Allarity Therapeutics
Phase 2 Terminated
NCT03753919 2026-03-11
DUTHY
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Terminated
NCT04832854 2026-03-11
A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 2 Terminated
NCT04166383 2026-03-10
VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC)
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT04179864 2026-03-10
CELLO-1
Ipsen
Phase 1/2 Terminated
NCT05537766 2026-03-10
ZUMA-25
Gilead Sciences
Phase 2 Terminated
NCT02946996 2026-03-05
Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients Receiving Androgen Deprivation Therapy
Medical University of South Carolina
Phase 2 Terminated
NCT03506373 2026-03-05
Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia
Mayo Clinic
Phase 2 Terminated
NCT04222972 2026-03-05
AcceleRET-Lung
Hoffmann-La Roche
Phase 3 Terminated
NCT04327700 2026-03-05
Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib
Wake Forest University Health Sciences
Phase 2 Terminated
NCT03772925 2026-03-03
Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
National Cancer Institute (NCI)
Phase 1 Terminated
NCT05554354 2026-03-03
Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Terminated
NCT03211988 2026-03-02
Entinostat Neuroendocrine (NE) Tumor
Columbia University
Phase 2 Terminated